<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01094704</url>
  </required_header>
  <id_info>
    <org_study_id>09-0670</org_study_id>
    <nct_id>NCT01094704</nct_id>
  </id_info>
  <brief_title>Durability of Hypertonic Saline for Enhancing Mucociliary Clearance in Cystic Fibrosis</brief_title>
  <official_title>Durability of Hypertonic Saline for Enhancing Mucociliary Clearance in Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Direct measurement of mucociliary and cough clearance (MCC/CC) has been used as a biomarker
      in cystic fibrosis (CF). Additional knowledge of the performance of this biomarker is needed
      to inform exploratory clinical trial design in support of programs to develop new inhaled
      therapies for CF. We hypothesize that MCC/CC measurements can be used to determine the
      durability of action of agents like hypertonic saline (HS) which increase epithelial lining
      fluid height.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A reduction in epithelial lining fluid height in cystic fibrosis (CF) as a consequence of
      decreased function of the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) chloride
      channel and related increased activity of the Epithelial sodium (Na) Channel (ENaC) results
      in impaired mucociliary clearance (MCC), mucus stasis, inflammation, infection, and
      ultimately progressive bronchiectasis. Inhalation of hypertonic saline (HS), through a direct
      osmotic effect on the airways, results in an increase in epithelial lining fluid height in
      vitro and an increase in MCC in vivo as measured following inhalation of a radiotracer with
      gamma scintigraphy (Sood, et al 2003). MCC as a biomarker is being validated in the clinic,
      as administration of inhaled hypertonic saline (HS) to cystic fibrosis patients results in
      short- and medium-term improvements in MCC (Donaldson, et al 2006), while long-term
      administration of HS is associated with improvements in the registration endpoints of lung
      function and pulmonary exacerbations (Elkins, et al 2006). Based in large part on these
      studies, HS has gained acceptance in the CF community, with estimates of up to 50% of
      patients being treated with this therapy. MCC/CC is thus an excellent choice as a Proof of
      Concept endpoint for exploratory clinical studies of ENaC modulators. Prior clinical
      experience with the ENaC blocker amiloride, which improves MCC acutely in healthy volunteers
      (Sood, et al 2003) but failed to improve lung function in long-term studies in CF (Pons, et
      al 2000), suggests that durable ENaC modulation will be required for clinical success. It is
      believed that modulation of ENaC for a period of at least 4 hours will be required to achieve
      the necessary durability. This durability should also enable twice daily dosing. For
      comparison we need to know the effectiveness of HS over this same period. Thus, this study is
      intended to assess 1) the duration of action out to 4 hours for inhaled hypertonic saline
      (7%) in adult CF patients and 2) the variability of MCC/CC measurements with and without HS
      treatment. These assessments at UNC will be compared to similar measures at Johns Hopkins
      University (JHU) for Novartis to determine the feasibility for future multicenter studies
      using MCC/CC as a primary endpoint.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Average Mucociliary Clearance (0-90 Minutes) at 1 and 4 Hrs Post Dose (MCC4hr - MCCbaseline; MCC1hr - MCCbaseline)</measure>
    <time_frame>1-4 hours post-dose</time_frame>
    <description>Duration of action of hypertonic saline as determined by measurements of mucociliary clearance/cough clearance 4 hours post dose.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Hypertonic Saline - 1 hour</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sodium chloride (7%); mucociliary clearance measured 1 hour post dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertonic Saline - 4 hours</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sodium chloride (7%); mucociliary clearance measured four hours post-dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium chloride (7%)</intervention_name>
    <description>4mL nebulized 7% sodium chloride</description>
    <arm_group_label>Hypertonic Saline - 1 hour</arm_group_label>
    <arm_group_label>Hypertonic Saline - 4 hours</arm_group_label>
    <other_name>Hyper-Sal</other_name>
    <other_name>Hypertonic saline (7%)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gender: Male or female (non-pregnant, non-lactating)

          -  Cystic fibrosis documented by a compatible clinical and radiographic presentation, and
             sweat chloride &gt; 60 mEq/l or 2 disease causing CFTR mutations.

          -  Severity of Disease:

               1. Must have FEV1 of greater than or equal to 50% of predicted at the screening
                  visit.

               2. Must have an oxygen saturation of &gt;92% on room air as determined by pulse
                  oximetry at the screening visit.

          -  Patient or legally authorized representative agrees to the patient/individual's
             participation in the study by signing and dating the informed consent form after the
             nature of the study has been fully explained and all questions have been
             satisfactorily answered.

        Exclusion Criteria:

          -  Unstable lung disease: As defined by a change in medical regimen during the preceding
             2 weeks; an FEV1 &gt;15% below recent (within 6 months) clinical measurements; or a
             significant new finding on chest radiograph (pneumothorax, lobar/segmental collapse)
             not considered a part of the usual, chronic progression of CF lung disease.

          -  Patients unable or unwilling to be withdrawn from hypertonic saline therapy, dornase
             alfa, or N-acetylcysteine 3 days prior to and for the duration of each Baseline and
             Treatment Period will be excluded.

          -  Patients unable to withhold use of long-acting bronchodilators (i.e., Salmeterol,
             Advair, Formoterol), anti-cholinergics, and vest therapy 12 hours prior to and for the
             duration of each treatment period.

          -  Patients unable to withhold short-acting bronchodilator 6 hours prior to and for the
             duration of each treatment period except as prescribed by the study protocol.

          -  Patients that have received an investigational drug or therapy during the preceding 30
             days.

          -  Patients that have had radiation exposure within the past year that would cause them
             to exceed Federal Regulations by participating in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Bennett, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med. 2006 Jan 19;354(3):241-50.</citation>
    <PMID>16421365</PMID>
  </reference>
  <reference>
    <citation>Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PT; National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med. 2006 Jan 19;354(3):229-40.</citation>
    <PMID>16421364</PMID>
  </reference>
  <reference>
    <citation>Bennett WD, Olivier KN, Zeman KL, Hohneker KW, Boucher RC, Knowles MR. Effect of uridine 5'-triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis. Am J Respir Crit Care Med. 1996 Jun;153(6 Pt 1):1796-801.</citation>
    <PMID>8665037</PMID>
  </reference>
  <reference>
    <citation>Donaldson SH, Boucher RC. Sodium channels and cystic fibrosis. Chest. 2007 Nov;132(5):1631-6. Review.</citation>
    <PMID>17998363</PMID>
  </reference>
  <reference>
    <citation>Pons G, Marchand MC, d'Athis P, Sauvage E, Foucard C, Chaumet-Riffaud P, Sautegeau A, Navarro J, Lenoir G. French multicenter randomized double-blind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients. The Amiloride-AFLM Collaborative Study Group. Pediatr Pulmonol. 2000 Jul;30(1):25-31.</citation>
    <PMID>10862159</PMID>
  </reference>
  <reference>
    <citation>Sood N, Bennett WD, Zeman K, Brown J, Foy C, Boucher RC, Knowles MR. Increasing concentration of inhaled saline with or without amiloride: effect on mucociliary clearance in normal subjects. Am J Respir Crit Care Med. 2003 Jan 15;167(2):158-63. Epub 2002 Oct 31.</citation>
    <PMID>12411282</PMID>
  </reference>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2010</study_first_submitted>
  <study_first_submitted_qc>March 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2010</study_first_posted>
  <results_first_submitted>September 26, 2011</results_first_submitted>
  <results_first_submitted_qc>July 17, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 21, 2012</results_first_posted>
  <last_update_submitted>July 17, 2012</last_update_submitted>
  <last_update_submitted_qc>July 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of North Carolina, Chapel Hill</investigator_affiliation>
    <investigator_full_name>Scott Donaldson</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>cystic fibrosis</keyword>
  <keyword>mucociliary clearance</keyword>
  <keyword>hypertonic saline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hypertonic Saline - 1 Hour</title>
          <description>Single dose of hypertonic saline (7%) nebulized followed by MCC/CC assessment one hour post-dose.</description>
        </group>
        <group group_id="P2">
          <title>Hypertonic Saline - 4 Hours</title>
          <description>Single dose of hypertonic saline (7%) nebulized followed by MCC/CC assessment four hours post-dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hypertonic Saline - 1 Hour</title>
          <description>Single dose of hypertonic saline (7%) nebulized followed by MCC/CC assessment one hour post-dose.</description>
        </group>
        <group group_id="B2">
          <title>Hypertonic Saline - 4 Hours</title>
          <description>Single dose of hypertonic saline (7%) nebulized followed by MCC/CC assessment four hours post-dose.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Average Mucociliary Clearance (0-90 Minutes) at 1 and 4 Hrs Post Dose (MCC4hr - MCCbaseline; MCC1hr - MCCbaseline)</title>
        <description>Duration of action of hypertonic saline as determined by measurements of mucociliary clearance/cough clearance 4 hours post dose.</description>
        <time_frame>1-4 hours post-dose</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Hypertonic Saline - 1 Hour</title>
            <description>Single dose of hypertonic saline (7%) nebulized followed by MCC/CC assessment one hour post-dose.</description>
          </group>
          <group group_id="O2">
            <title>Hypertonic Saline - 4 Hours</title>
            <description>Single dose of hypertonic saline (7%) nebulized followed by MCC/CC assessment four hours post-dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Average Mucociliary Clearance (0-90 Minutes) at 1 and 4 Hrs Post Dose (MCC4hr - MCCbaseline; MCC1hr - MCCbaseline)</title>
          <description>Duration of action of hypertonic saline as determined by measurements of mucociliary clearance/cough clearance 4 hours post dose.</description>
          <population>ITT</population>
          <units>Absolute % change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="8.9"/>
                    <measurement group_id="O2" value="6.7" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Hypertonic Saline - 1 Hour</title>
          <description>Single dose of hypertonic saline (7%) nebulized followed by MCC/CC assessment one hour post-dose.</description>
        </group>
        <group group_id="E2">
          <title>Hypertonic Saline - 4 Hours</title>
          <description>Single dose of hypertonic saline (7%) nebulized followed by MCC/CC assessment four hours post-dose.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Scott Donaldson</name_or_title>
      <organization>UNC-Chapel Hill</organization>
      <phone>919-966-9198</phone>
      <email>scott_donaldson@med.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

